dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Malik, Zafar |
dc.contributor.author | Di Lorenzo, Giuseppe |
dc.contributor.author | Pichler, Angelika |
dc.contributor.author | Hitier, Simon |
dc.contributor.author | Ecstein-Fraisse, Evelyne |
dc.contributor.author | Carles Galceran, Joan |
dc.contributor.author | De Giorgi, Ugo |
dc.date.accessioned | 2021-08-25T10:33:26Z |
dc.date.available | 2021-08-25T10:33:26Z |
dc.date.issued | 2020-04-17 |
dc.identifier.citation | Malik Z, Di Lorenzo G, Pichler A, De Giorgi U, Hitier S, Ecstein-Fraisse E, et al. Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry. Cancers. 2020 Apr 17;12(4):995. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/6236 |
dc.description | mCRPC; Cabazitaxel; CAPRISTANA |
dc.description.sponsorship | This research was funded by Sanofi. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;12(4) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Pròstata - Càncer |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject.mesh | Prostatic Neoplasms, Castration-Resistant |
dc.subject.mesh | /drug therapy |
dc.title | Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers12040995 |
dc.subject.decs | neoplasias prostáticas resistentes a la castración |
dc.subject.decs | /farmacoterapia |
dc.relation.publishversion | https://www.mdpi.com/2072-6694/12/4/995 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Malik Z] Clinical Oncology, The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, UK. [Di Lorenzo G] Department of Medicine and Health Sciences ‘Vincenzo Tiberio’, University of Molise, Campobasso, Italy. Medical Oncology, Tortora Hospital, Pagani, Salerno, Italy. [Pichler A] Department of Hematology and Oncology, Regional Hospital Hochsteiermark, Leoben, Austria. [De Giorgi U] Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. [Hitier S] Department of Biostatistics, Sanofi, Chilly-Mazarin, France. [Ecstein-Fraisse E] Medical Evidence Generation, Sanofi, Paris, France. [Carles J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 32316580 |
dc.identifier.wos | 000535587400223 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |